Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Knoll Meridia

Executive Summary

Two-year safety data added to labeling from the company's STORM study. While Knoll reports that 70% of patients in the study maintained a 5% weight loss for the duration of the study compared to 44% of placebo patients, only safety data from the study was added to labeling. Meridia revised labeling states that the "safety and effectiveness...have not been determined beyond two years at this time." Previously, labeling limited the experience to one year from trials conducted for approval of the drug. Labeling also adds blood pressure data from a 26-patient study showing increases in systolic and diastolic blood pressure for the drug compared to placebo. Meridia labeling contains a warning about substantial increases in blood pressure. Meridia had sales of $94.5 mil. in 2000 compared to $201 mil. for Roche's Xenical, according to IMS Health data

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts